A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex.
A low-dose mitotane (MT) regimen was evaluated as a pharmacological approach for correcting the severe hypercortisolism in a young woman affected by Carney complex (CNC) and primary pigmented nodular adrenocortical disease (PPNAD). In the first 12 week period, the MT daily dose was progressively increased from 0.5 to 4.0 g/day. This dosage was maintained for an additional 16 weeks (cumulative dose 602 g, plasma MT maximum level 12 microg/ml), and then stopped because of sustained signs of hypoadrenalism requiring prednisone replacement. Complete regression of seborrhea, acne, and plethora was observed after 8 weeks of treatment (cumulative dose 95 g). Regular menses returned after 13 weeks (cumulative dose 197 g, plasma MT 8 microg/ml). Profound decrease of both serum cortisol (from 615 to 220 nmol/l) and urinary free cortisol (UFC) values (from 1498 to 477 nmol/day) was noted after 16 weeks of treatment (cumulative dose 314 g, plasma MT 8 microg/ml). MT treatment was associated with mild gastric discomfort and reversible increase of cholesterol plasma levels. Low serum cortisol and UFC were still observed 41 weeks after MT was discontinued (plasma MT 0.2 microg/ml). Our report demonstrates that low dose MT treatment may be a safe and effective modality for a sustained correction of hypercortisolism by PPNAD in subjects with CNC waiting for surgery.
Cignarelli
M
M
Endocrinology and Metabolic Diseases, University of Foggia, Foggia, Italy. cignarelli@tiscali.it
Picca
G
G
Campo
M
M
Margaglione
M
M
Marino
A
A
Logoluso
F
F
Giorgino
F
F
D000303:Adrenal Cortex Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000311:Adrenal Glands / Q000000981:diagnostic imaging / Q000473:pathology; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004247:DNA / Q000235:genetics; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood* / Q000652:urine; D008134:Long-Term Care; D008668:Metallothionein / Q000097:blood; D008939:Mitotane / Q000627:therapeutic use*; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010859:Pigmentation Disorders / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013256:Steroids / Q000097:blood; D013577:Syndrome; D014057:Tomography, X-Ray Computed
D018931:Antineoplastic Agents, Hormonal; D013256:Steroids; D008939:Mitotane; D004247:DNA; D008668:Metallothionein; D006854:Hydrocortisone